Form 144 Notice: Ionis Insider Sale of 51,800 Shares via Stifel
Rhea-AI Filing Summary
Ionis Pharmaceuticals Form 144 notice: A proposed sale of 51,800 shares of common stock is reported to be executed through Stifel Nicolaus & Company, Inc. on 09/03/2025 with an aggregate market value of $3,152,698.00. The filing lists total shares outstanding of 159,391,229. Acquisition details for the shares to be sold are disclosed: 46,800 were acquired by option exercise on 01/03/2022, 7,537 were restricted stock units dated 01/15/2017, and 6,373 were restricted stock units dated 01/15/2016. The filing also reports sales by Frank Bennett in the past three months: 10,000 shares on 08/18/2025 for $439,776.00, and two sales on 09/02/2025 of 2,374 (proceeds $116,658.00) and 2,626 (proceeds $129,042.00). The filer signs a standard representation that no material nonpublic information is known. Other issuer contact and relationship fields are not populated in the provided content.
Positive
- Proposed sale disclosed with specific trade date (09/03/2025), broker (Stifel) and aggregate market value ($3,152,698.00).
- Acquisition history provided for the shares to be sold with dates and transaction types (option exercise and RSUs).
- Prior sales listed for the past three months with amounts and gross proceeds (totaling 15,000 shares).
Negative
- Issuer and relationship fields are not populated in the provided content, limiting context about the seller's role.
- Filing does not state whether the seller is an officer, director, or large shareholder in the provided excerpt.
Insights
TL;DR: Routine insider sale filing disclosing 51,800 shares for $3.15M, with prior small sales by Frank Bennett.
The Form 144 is procedural: it notifies the SEC of a proposed sale of 51,800 Ionis common shares through Stifel on 09/03/2025 valued at $3,152,698. The filing details the acquisition method and dates for the lots to be sold, indicating option exercise and restricted stock unit origins. Reported prior sales by Frank Bennett total 15,000 shares across August and September 2025 with disclosed gross proceeds. The filing does not include issuer relationship or additional context about the seller's role, limiting inference about insider status or intent.
TL;DR: Disclosure appears compliant but lacks populated issuer relationship and contact fields, leaving some contextual gaps.
The submitted Form 144 contains the essential trading specifics required for Rule 144 notices: class, broker, amounts, acquisition dates, and past three-month sales. However, several issuer information fields (issuer contact, relationship to issuer) are blank in the provided content, which reduces transparency about the seller's capacity. The filing includes the statutory attestation regarding absence of material nonpublic information, consistent with rule requirements.